Distinguished in Raynaud Phenomenon

Dr. Laura K. Hummers

Rheumatology
Johns Hopkins University
5501 Hopkins Bayview Cir, 
Baltimore, MD 
Accepting New Patients
Offers Telehealth
Distinguished in Raynaud Phenomenon
Johns Hopkins University
5501 Hopkins Bayview Cir, 
Baltimore, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Laura Hummers is a Rheumatologist in Baltimore, Maryland. Dr. Hummers is rated as a Distinguished provider by MediFind in the treatment of Raynaud Phenomenon. Her top areas of expertise are Scleroderma, Systemic Sclerosis (SSc), Eosinophilic Fasciitis, and Scleroma. Dr. Hummers is currently accepting new patients.

Her clinical research consists of co-authoring 138 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 9 articles in the study of Raynaud Phenomenon.

Specialties
Rheumatology
Licenses
Internal Medicine in MD
Hospital Affiliations
The Johns Hopkins Hospital
Johns Hopkins Bayview Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
HMSA
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Northwell Health
  • INSURANCE PLAN
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

JOHNS HOPKINS UNIVERSITY
5501 Hopkins Bayview Cir, Baltimore, MD 21224

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics, and Explore Efficacy of TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis
A Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics, and Explore Efficacy of TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: June 28, 2024
Intervention Type: Biological, Other
Study Drug: Tepezza Anti-IGF-1 Receptor Monoclonal Antibody
Study Phase: Phase 1
Evaluation of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis BRAVOS: A Phase 1/2 Multicenter Randomized, Double Blinded, Safety Study (ITN075AI)
Evaluation of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis BRAVOS: A Phase 1/2 Multicenter Randomized, Double Blinded, Safety Study (ITN075AI)
Enrollment Status: Completed
Publish Date: May 17, 2024
Intervention Type: Biological
Study Drug: Brentuximab vedotin
Study Phase: Phase 1/Phase 2
Scleroderma Lung Study III (SLS III): Combining the Anti-fibrotic Effects of Pirfenidone (PFD) With Mycophenolate (MMF) for Treating Scleroderma-related Interstitial Lung Disease
Scleroderma Lung Study III (SLS III): Combining the Anti-fibrotic Effects of Pirfenidone (PFD) With Mycophenolate (MMF) for Treating Scleroderma-related Interstitial Lung Disease
Enrollment Status: Completed
Publish Date: December 15, 2023
Intervention Type: Drug
Study Drugs: Pirfenidone, Mycophenolate Mofetil
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Other, Biological, Drug, Diagnostic test
Study Phase: Phase 2
A Multi-center, Randomized, Double-blind (Sponsor Open), Placebo-controlled, Repeat-dose, Proof of Mechanism Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Explore Efficacy of GSK2330811 in Participants With Diffuse Cutaneous Systemic Sclerosis
A Multi-center, Randomized, Double-blind (Sponsor Open), Placebo-controlled, Repeat-dose, Proof of Mechanism Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Explore Efficacy of GSK2330811 in Participants With Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Completed
Publish Date: May 24, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: March 29, 2021
Intervention Type: Drug, Other
Study Phase: Phase 3
A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Efficacy of Intravenous Immunoglobulin Treatment in Patients With Systemic Sclerosis
A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Efficacy of Intravenous Immunoglobulin Treatment in Patients With Systemic Sclerosis
Enrollment Status: Unknown
Publish Date: July 17, 2018
Intervention Type: Biological
Study Phase: Not Applicable
View 6 Less Clinical Trials

138 Total Publications

Refining Risk Prediction in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.
Refining Risk Prediction in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.
Journal: Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
Published: April 11, 2025
Similar Doctors
Elite in Raynaud Phenomenon
Dr. Fredrick M. Wigley
Rheumatology
Elite in Raynaud Phenomenon
Dr. Fredrick M. Wigley
Rheumatology

Johns Hopkins University

5501 Hopkins Bayview Cir, 
Baltimore, MD 
 (0.1 miles away)
410-550-0545
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Fredrick Wigley is a Rheumatologist in Baltimore, Maryland. Dr. Wigley is rated as a Distinguished provider by MediFind in the treatment of Raynaud Phenomenon. His top areas of expertise are Scleroderma, Systemic Sclerosis (SSc), Raynaud Phenomenon, and Scleroma. Dr. Wigley is currently accepting new patients.

Distinguished in Raynaud Phenomenon
Dr. Sam W. Serafi
Rheumatology
Distinguished in Raynaud Phenomenon
Dr. Sam W. Serafi
Rheumatology

Rheumatology Associates Of Baltimore LLC

1220B East Joppa Road, Suite 324, Towson, 
Baltimore, MD 
 (8.6 miles away)
410-494-1888
Languages Spoken:
English
See accepted insurances

Sam Serafi is a Rheumatologist in Baltimore, Maryland. Dr. Serafi is rated as a Distinguished provider by MediFind in the treatment of Raynaud Phenomenon. His top areas of expertise are Fibromyalgia, Raynaud Phenomenon, Sjogren Syndrome, and Rheumatoid Arthritis (RA).

Distinguished in Raynaud Phenomenon
Dr. Howard W. Hauptman
Rheumatology
Distinguished in Raynaud Phenomenon
Dr. Howard W. Hauptman
Rheumatology

Rheumatology Associates Of Baltimore LLC

1220B East Joppa Road, Suite 324, Towson, 
Baltimore, MD 
 (8.6 miles away)
410-494-1888
Experience:
43+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Howard Hauptman is a Rheumatologist in Baltimore, Maryland. Dr. Hauptman has been practicing medicine for over 43 years and is rated as a Distinguished provider by MediFind in the treatment of Raynaud Phenomenon. His top areas of expertise are Rheumatoid Arthritis (RA), Rhizomelic Pseudopolyarthritis, Sjogren Syndrome, and Polymyalgia Rheumatica. Dr. Hauptman is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hummers's expertise for a condition
ConditionClose
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile